基药目录管理办法解读专家会

Summary of Conference Call on Essential Drug Directory Management Measures Industry Overview - The conference focuses on the essential drug policy in China, specifically the newly released management measures for the essential drug directory by the National Health Commission and ten other ministries, which is seen as a significant policy development after a long wait of 4-5 years [1][2]. Key Points and Arguments 1. Policy Launch and Timeline: - The management measures aim to accelerate the completion of the essential drug directory by the end of February, with a final announcement expected shortly after the National People's Congress in March [6][7]. - The initial screening of products has already been completed, and expert evaluations are ongoing [6]. 2. Selection Principles: - The new measures clarify the selection and adjustment principles for the essential drug directory, emphasizing the involvement of a diverse expert group, including public health, medical ethics, and pharmacoeconomics experts [3][4]. - The focus is on clinical needs and drug economic evaluations, which will guide the selection process [10]. 3. Importance of Essential Drug Status: - The essential drug status is crucial for products to enter hospitals, as it provides a competitive advantage in the market [9]. - Products that are both essential drugs and included in the medical insurance directory will have a higher likelihood of being adopted in hospitals [9]. 4. Concerns Over Supporting Policies: - There are concerns about whether accompanying policies will support the implementation of the new essential drug directory, especially in terms of hospital adoption and reimbursement [8][10]. - The expert reassured that the essential drug identity will remain significant, and there is potential for a market surge in this sector [10]. 5. Unique Product Review: - Unique products, particularly in traditional Chinese medicine, will undergo separate discussions to ensure their pricing and economic viability are justified [17][19]. - The review process aims to prevent high pricing and potential corruption, ensuring that only reasonably priced unique products are considered [17]. 6. Market Dynamics and Product Categories: - The expert predicts that traditional Chinese medicine injections may face challenges in being included in the new directory due to regulatory and application issues [20]. - The adjustment of the directory will likely favor chemical drugs that have undergone significant advancements in safety and efficacy [21][22]. 7. Potential for Reimbursement Adjustments: - There is speculation that some essential drugs may be reclassified from Category B to Category A in the reimbursement system, which would enhance their market appeal [23]. 8. Focus Areas for Inclusion: - The expert highlighted that pediatric, oncology, pain management, and otolaryngology products are likely to see more inclusions in the new directory, while respiratory and gastrointestinal products may have lower chances [25][29]. 9. Historical Sales as a Predictor: - Historical sales data and the coverage of medical institutions will be critical indicators for predicting which products are likely to be included in the essential drug directory [14][15]. 10. Differentiation in Naming Conventions: - The conference also discussed the differences in naming conventions between traditional Chinese medicine and chemical drugs, emphasizing that the generic names for Chinese medicine include dosage forms, which affects their inclusion in the directory [32][33]. Other Important Insights - The expert emphasized the need for ongoing monitoring of policy developments and the potential for future supportive measures to enhance the essential drug directory's effectiveness [12][13]. - The discussion highlighted the importance of clinical data and expert familiarity with products as key factors in the selection process for the essential drug directory [15][19].